DT Cloud Star Acquisition Corp announced a business combination agreement with biotech firm PrimeGen US, Inc. and received a Nasdaq deficiency notice for minimum public shareholder requirements.

• On February 2, 2026, DT Cloud Star Acquisition Corp entered into a Business Combination Agreement with PrimeGen US, Inc., a biotech company, to effect a merger and take the target public [S1].
• On April 6, 2026, the company received a Nasdaq deficiency notice for non-compliance with the minimum public shareholder requirement, with a grace period to regain compliance before potential delisting proceedings [S2][S13].
• The company’s units began trading on Nasdaq in July 2024, with ordinary shares and rights trading separately since September 2024 [S1].
• PrimeGen is reported in public news as going public via the SPAC deal with DT Cloud Star Acquisition Corp [N1].

The company’s experienced management team and extensive network may enable it to identify and acquire a high-quality target with strong growth potential and defensible market position. The announced business combination with PrimeGen, a biotech firm, could provide a pathway to public markets for the target, leveraging the SPAC’s capital and public listing benefits. The flexibility in deal structuring and access to capital markets expertise may facilitate value creation post-combination. The SPAC structure offers a potentially faster and less costly alternative to traditional IPOs for the target company.

The company’s business model depends on successfully completing a business combination, which is subject to negotiation, shareholder approval, and closing conditions, with no guarantee of consummation. Financially, the company shows limited liquidity and a low current ratio, which may constrain operational flexibility. The Nasdaq deficiency notice for minimum public shareholder requirements poses a risk of delisting, which could adversely affect liquidity and market perception. Competition from other SPACs and acquisition entities may limit access to attractive targets. The initial shareholders’ significant ownership stake may influence decisions in ways not aligned with all shareholders. The biotech target’s inherent risks, including regulatory and commercialization challenges, add to execution uncertainty.

As a blank check company, DT Cloud Star Acquisition Corp’s moat is primarily derived from its management team’s experience, network, and ability to source and execute attractive business combinations. The management’s track record in private equity and capital markets, combined with access to a broad network of industry contacts and financial intermediaries, provides differentiated deal sourcing capabilities. The company’s structure as a publicly traded SPAC offers an alternative route to public markets for target companies, potentially providing a competitive advantage in attracting acquisition candidates. However, the moat is contingent on successful identification and consummation of a business combination, which carries inherent execution risks.

• Nasdaq Listing Compliance Risk: The company received a deficiency notice from Nasdaq for failing to meet the minimum public shareholder requirement, with potential delisting proceedings if not remedied, which could reduce stock liquidity and adversely affect market price [S2][S13].
• Business Combination Execution Risk: Completion of the business combination is subject to negotiation, definitive agreement execution, closing conditions, and shareholder approval, with no assurance of consummation in the near term [S1].
• Financial Liquidity Risk: As of March 31, 2026, the company had limited cash and a low current ratio (0.08), indicating constrained liquidity to support operations or unforeseen expenses [S2].
• Competitive Risk: The company faces competition from other SPACs, private equity firms, and investment entities with greater resources, which may limit access to attractive acquisition targets [S21].
• Concentration of Control: Initial shareholders own approximately 52.9% of the company’s shares, potentially influencing shareholder votes and decisions in ways not aligned with all shareholders [S21].
• Target Company Risks: The target company, PrimeGen, operates in biotech, a sector with inherent risks including regulatory approvals, commercialization challenges, and capital requirements [N1][S4][S6].

• DT Cloud Star Acquisition Corp is a blank check company incorporated in the Cayman Islands on November 29, 2022, formed to effect a business combination with one or more target businesses [S1].
• The company completed its initial public offering on July 26, 2024, raising gross proceeds of $69 million, with an additional private placement of $2.07 million from its sponsor [S1].
• The units began trading on Nasdaq under the symbol DTSQU on July 25, 2024; ordinary shares and rights trade under DTSQ and DTSQR respectively [S1].
• Management is actively seeking a business combination without limitation to industry or geography, with a focus on targets having significant growth prospects and competitive advantages [S1].
• The management team is led by CEO Sam Zheng Sun, who has private equity and venture capital experience in Asia and holds an MBA from UCLA Anderson [S1].
• The company entered into a Business Combination Agreement on February 2, 2026, with PrimeGen US, Inc., a Delaware corporation, as the target business [S1].
• Financial snapshot as of March 31, 2026, shows cash and equivalents of $1.656 million, current assets of $73.858 million, and current liabilities of $928.408 million, resulting in a current ratio of 0.08 and a cash ratio of 0 [S2].
• Net loss for the quarter ending March 31, 2026, was $110.289 thousand [S2].
• Basic and diluted EPS were -$0.028 per share as of June 30, 2024 [S2].
• The company received a Nasdaq deficiency notice on April 6, 2026, for non-compliance with the minimum public shareholder requirement, with potential delisting risk if not remedied [S2][S13].
• The company’s acquisition strategy includes leveraging management’s operational expertise, deal experience, and extensive networks to identify targets with strong market positions, recurring revenue, and growth potential [S1].
• The company intends to use proceeds from its IPO and private placement held in trust to fund the business combination, with flexibility to use cash, debt, or equity securities [S1].
• The company’s business combination is subject to negotiation, definitive agreement execution, closing conditions, and shareholder approval, with no assurance of consummation in the near term [S1].
• The company’s management team has decades of combined experience in growth strategies, capital allocation, and operational improvements [S1].
• The company’s competitive strengths include seasoned management, differentiated deal sourcing, strong understanding of public and private markets, and robust execution and structuring capabilities [S1].
• The company’s initial shareholders own approximately 52.9% of issued shares, potentially influencing shareholder votes [S21].
• Recent news reports that PrimeGen, the target company, is to go public via the SPAC deal with DT Cloud Star Acquisition Corp [N1].